<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="205">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05158478</url>
  </required_header>
  <id_info>
    <org_study_id>IDK_ISO_2021_005</org_study_id>
    <nct_id>NCT05158478</nct_id>
  </id_info>
  <brief_title>Hematocrit Effect on a Blood Glucose Monitor</brief_title>
  <official_title>Evaluation of the Hematocrit Effect on the Blood Glucose Monitor for Personal Use JT100</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut fur Diabetes Karlsburg GmbH</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Tyson Bioresearch Inc., Kedong 3rd Rd., Zhunan Township, Miaoli County 35053, Taiwan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Institut fur Diabetes Karlsburg GmbH</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study assesses the repeatability precision of a blood glucose monitoring system pursuant&#xD;
      to ISO 15197&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study assesses the repeatability precision the blood glucose monitoring systems for&#xD;
      personal use TJ100 pursuant to ISO 15197:2015 guidelines&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 15, 2022</start_date>
  <completion_date type="Anticipated">January 20, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 16, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>repeatability precision</measure>
    <time_frame>day 1</time_frame>
    <description>Assessment of the analytical measurement performance of the blood glucose monitor based on procedures defined in DIN EN ISO 15197</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">2</enrollment>
  <condition>Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Subject glucometer measurement</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>blood glucose measurement, blood glucose monitor for personal use</intervention_name>
    <description>measurement of the blood glucose concentration using the blood glucose monitor for personal use (TJ100)</description>
    <arm_group_label>Subject glucometer measurement</arm_group_label>
    <other_name>measurement of the blood glucose concentration using the blood glucose monitor for personal use (TJ100)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>blood glucose measurement, laboratory reference device</intervention_name>
    <description>measurement of the blood glucose concentration using a laboratory reference device (YSI 2300 Stat Plus)</description>
    <arm_group_label>Subject glucometer measurement</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female patients with clinical indication for blood glucose testing&#xD;
&#xD;
          -  Signed form of consent&#xD;
&#xD;
          -  Minimum age of 18 years&#xD;
&#xD;
          -  Subjects are legally competent and capable to understand character, meaning and&#xD;
             consequences of the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy or lactation&#xD;
&#xD;
          -  Severe acute disease (at study physician's discretion)&#xD;
&#xD;
          -  Acute or chronic diseases with inherent risk of aggravation by the procedure (at study&#xD;
             physician's discretion)&#xD;
&#xD;
          -  Current constitution that does not allow participating in the study (e.g. hematocrit&#xD;
             out of&#xD;
&#xD;
          -  the devices's specifications, medication known to influence blood glucose&#xD;
             measurements; Appendix A of ISO 15197)&#xD;
&#xD;
          -  Being unable to give informed consent&#xD;
&#xD;
          -  Age younger than 18 years&#xD;
&#xD;
          -  Legally incompetent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eckhard Salzsieder, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Institut fur Diabetes Karlsburg GmbH</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Eckhard Salzsieder, PhD</last_name>
    <phone>+49493835568437</phone>
    <email>salzsied@diabetes-karlsburg.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Matthes Kenning, PhD</last_name>
    <phone>+493835568428</phone>
    <email>mkenning@diabetes-karlsburg.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Institut f√ºr Diabetes Karlsburg GmbH</name>
      <address>
        <city>Karlsburg</city>
        <state>Mecklenburg Vorpommern</state>
        <zip>17495</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>December 2021</verification_date>
  <study_first_submitted>December 2, 2021</study_first_submitted>
  <study_first_submitted_qc>December 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 15, 2021</study_first_posted>
  <last_update_submitted>December 2, 2021</last_update_submitted>
  <last_update_submitted_qc>December 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Institut fur Diabetes Karlsburg GmbH</investigator_affiliation>
    <investigator_full_name>Matthes Kenning</investigator_full_name>
    <investigator_title>Dr. Eckhard Salzsieder</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

